Treatment Alternatives for Hepatitis B Cirrhosis: A Cost-Effectiveness Analysis

Kanwal, Fasiha; Farid, Mary; Martin, Paul; Chen, Gary; Gralnek, Ian M.; Dulai, Gareth S.; Spiegel, Brennan M. R.
September 2006
American Journal of Gastroenterology;Sep2006, Vol. 101 Issue 9, p2076
Academic Journal
BACKGROUND: Hepatitis B virus (HBV) patients with cirrhosis are at risk for developing costly, morbid, or mortal events, and therefore need highly effective therapies. Lamivudine is effective but is limited by viral resistance. In contrast, adefovir and entecavir have lower viral resistance, but are more expensive. The most cost-effective approach is uncertain. METHODS: We evaluated the cost-effectiveness of six strategies in HBV cirrhosis: (1) No HBV treatment (“do nothing”), (2) lamivudine monotherapy, (3) adefovir monotherapy, (4) lamivudine with crossover to adefovir on resistance (“adefovir salvage”), (5) entecavir monotherapy, or (6) lamivudine with crossover to entecavir on resistance (“entecavir salvage”). The primary outcome was the incremental cost per quality-adjusted life-year (QALY) gained. RESULTS: The “do nothing” strategy was least effective yet least expensive. Compared with “do nothing,” using adefovir cost an incremental $19,731. Entecavir was more effective yet more expensive than adefovir, and cost an incremental $25,626 per QALY gained versus adefovir. Selecting between entecavir versus adefovir was highly dependent on the third-party payer's “willingess-to-pay” ( e.g., 45% and 60% of patients fall within budget if willing-to-pay $10K and $50K per QALY gained for entecavir, respectively). Both lamivudine monotherapy and the “salvage” strategies were not cost-effective. However, between the two salvage strategies, “adefovir salvage” was more effective and less expensive than “entecavir salvage.” CONCLUSION: Both entecavir and adefovir are cost-effective in patients with HBV cirrhosis. Choosing between adefovir and entecavir is highly dependent on available budgets. In patients with HBV cirrhosis with previous lamivudine resistance, “adefovir salvage” appears more effective and less expensive than “entecavir salvage.”


Related Articles

  • Entecavir of benefit in HBeAg-positive Hep B.  // PharmacoEconomics & Outcomes News;12/1/2007, Issue 542, p9 

    The article focuses on the findings of a study on the cost effectiveness of entecavir versus lamivudine for the treatment of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. It cites the 10-year cumulative incidence of cirrhosis for patients initiated on entecavir would...

  • Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis. Ooga, Hiromi; Suzuki, Fumitaka; Tsubota, Akihito; Arase, Yasuji; Suzuki, Yoshiyuki; Akuta, Norio; Sezaki, Hitomi; Hosaka, Tetsuya; Someya, Takashi; Kobayashi, Masahiro; Saitoh, Satoshi; Ikeda, Kenji; Kobayashi, Mariko; Matsuda, Marie; Satoh, Junko; Kumada, Hiromitsu // Journal of Gastroenterology;2004, Vol. 39 Issue 11, p1078 

    Background. Several clinical trials have suggested that lamivudine therapy is effective in patients with hepatitis B virus (HBV)-related cirrhosis. However, there are few studies of lamivudine therapy in Japanese patients with HBV cirrhosis. The aim of this study was to evaluate the efficacy of...

  • Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis. Schiff, Eugene; Simsek, Halis; Lee, William M.; You-Chen Chao; Sette Jr., Hoel; Janssen, Harry L. A.; Steven-Huy Han; Goodman, Zachary; Yang, Joanna; Brett-Smith, Helena; Tamez, Ricardo // American Journal of Gastroenterology;Nov2008, Vol. 103 Issue 11, p2776 

    OBJECTIVE: The efficacy and safety of entecavir in patients with chronic hepatitis B and advanced liver fibrosis/cirrhosis was assessed from three large, randomized, multicenter, phase III studies. PATIENTS AND METHODS: These studies enrolled patients (≥16 yr) with chronic hepatitis B,...

  • Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Fattovich, G.; Olivari, N.; Pasino, M.; D'Onofrio, M; Martone, E.; Donato, F. // Gut;Jan2008, Vol. 57 Issue 1, p84 

    Objective: To assess risk factors for liver-related death, we re-evaluated, after a median follow-up of 25 years, a cohort of 70 Caucasian patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis (CH) at presentation. Methods: Follow-up studies included clinical and ultrasound...

  • Clinical Course and Survival after Liver Transplantation for Hepatitis B Virus Infection Complicated by Hepatocellular Carcinoma. Wong, P. Y. N.; McPeake, J. R.; Portmann, B.; Path, F. R. C.; Tan, K.-C.; Naoumov, N. V.; Williams, Roger // American Journal of Gastroenterology;Jan1995, Vol. 90 Issue 1, p29 

    Objectives and Methods: The outcome after liver transplantation for HBsAg-positive liver disease complicated by hepatocellular carcinoma is not clearly defined, and in the present study we analyzed the clinical course in 39 patients transplanted for hepatitis B virus (HBV)-related liver disease...

  • Nutritional Status in Cirrhotic Patients. TEIUSANU, Adriana; ANDREI, Mihai; ARBANAS, Tudor; NICOLAIE, Tudor; DICULESCU, Mircea // Romanian Journal of Medical Practice;2012, Vol. 7 Issue 4, p284 

    Background: Malnutrition is prevalent in all forms of liver disease: from 20% in compensated liver disease to more than 80% in those patients with decompensated liver disease. Protein-calorie malnutrition (PCM) can be identified in all clinical stages but is easier observed in advanced stages of...

  • Clinical significance of genotypes and precore/basal core promoter mutations in HBV related chronic liver disease patients in North India. Sharma, Sanjeev; Sharma, Balkrishan; Singla, Bhupesh; Chawla, Yogesh Kumar; Chakraborti, Anuradha; Saini, Nitin; Duseja, Ajay; Das, Ashim; Dhiman, Radha Krishan // Digestive Diseases & Sciences;Mar2010, Vol. 55 Issue 3, p794 

    Purpose: Data on genotypes, basal core promoter (BCP) and precore mutants of hepatitis B virus and their association with different HBV related liver disease have been studied inadequately and are controversial. Thus, the aim of this study was to determine the incidence of BCP and...

  • Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. Jingjing Lu; Aiqiang Xu; Jian Wang; Li Zhang; Lizhi Song; Renpeng Li; Shunxiang Zhang; Guihua Zhuang; Mingshan Lu // BMC Health Services Research;2013, Vol. 13 Issue 1, p1 

    Background: Although the expenses of liver cirrhosis are covered by a critical illness fund under the current health insurance program in China, the economic burden associated with hepatitis B virus (HBV) related diseases is not well addressed. In order to provide evidence to address the...

  • Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection. Bolukbas, Cengiz; Filiz Bolukbas, Fusun; Horoz, Mehmet; Aslan, Mehmet; Celik, Hakim; Erel, Ozcan // BMC Infectious Diseases;2005, Vol. 5 Issue 1, p95 

    Background: Oxidative stress can be defined as an increase in oxidants and/or a decrease in antioxidant capacity. There is limited information about the oxidative status in subjects with hepatitis B virus infection. We aimed to evaluate the oxidative status in patients with various clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics